Δ9-Tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture

Neuropharmacology

Volumn 46, Issue 5, 2004, Pages 709-715

  Kelley, Brooke G ^a   Thayer, Stanley A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

2 Arachidonyl glycerol; Cannabinoid; CB1; Excitatory synaptic transmission; Hippocampus; Tetrahydrocannabinol

Indexed keywords

2 ARACHINODYLGLYCEROL; CALCIUM; CANNABINOID; CANNABINOL; DRONABINOL; INDO 1; MAGNESIUM; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATTENUATION; CALCIUM CELL LEVEL; CONCENTRATION RESPONSE; DRUG EFFICACY; FETUS; HIPPOCAMPUS; MICROFLUOROMETRY; NERVE CELL CULTURE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SPIKE WAVE; SYNAPTIC TRANSMISSION;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; FEMALE; HIPPOCAMPUS; NEURONS; PREGNANCY; RATS; SYNAPTIC TRANSMISSION; TETRAHYDROCANNABINOL;

EID: 1442299855     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2003.11.005     Document Type: Article

References (39)

1. Abood M.E., Martin B.R. Neurobiology of marijuana abuse. Trends in Pharmacological Sciences. 13:1992;201-206.
2. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology. 353:1998;23-31.
3. Berrendero F., Sepe N., Ramos J.A., Di Marzo V., Fernandez-Ruiz J.J. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse. 33:1999;181-191.
4. Breivogel C.S., Childers S.R. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. Journal of Pharmacology and Experimental Therapeutics. 295:2000;328-336.
5. Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Vogt L.J., Sim-Selley L.J. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. Journal of Neurochemistry. 73:1999;2447-2459.
6. Darmani N.A. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by Delta(9)-tetrahydrocannabinol and other cannabinoids. Journal of Pharmacology and Experimental Therapeutics. 300:2002;34-42.
7. De Lean A., Munson P.J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. American Journal of Physiology. 235:(2):1978;E97-E102.
8. Fowler C.J. Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents - non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolarnine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Research Reviews. 41:2003;26-43.
9. Glass M., Northup J.K. Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Molecular Pharmacology. 56:1999;1362-1369.
10. 2+ indicators with greatly improved fluorescence properties. Journal of Biological Chemistry. 260:1985;3440-3450.
11. Hampson R.E., Deadwyler S.A. Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. Journal of Neuroscience. 20:2000;8932-8942.
12. Howlett A.C. The CB1 cannabinoid receptor in the brain. Neurobiology of Disease. 5:1998;405-416.
13. Kelley B., Thayer S.A. THC acts as an antagonist to the endocannabinoid 2-arachidonyl glycerol. The 13th Annual International Cannabinoid Research Society Symposium:2003.
14. Kouznetsova M., Kelley B., Shen M., Thayer S.A. Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. Molecular Pharmacology. 61:2002;477-485.
15. Kreitzer A.C., Regehr W.G. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. Journal of Neuroscience. 21:2001a;RC174.
16. Kreitzer A.C., Regehr W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 29:2001b;717-727.
17. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Molecular Pharmacology. 44:1993;498-503.
18. Maejima T., Ohno-Shosaku T., Kano M. Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neuroscience Research. 40:2001;205-210.
19. Malone D.T., Taylor D.A. Modulation of delta9-tetrahydrocannabinol- induced hypothermia by fluoxetine in the rat. British Journal of Pharmacology. 124:1998;1419-1424.
20. McLeod J.R. Jr., Shen M., Kim D.J., Thayer S.A. Neurotoxicity mediated by aberrant patterns of synaptic activity between rat hippocampal neurons in culture. Journal of Neurophysiology. 80:1998;2688-2698.
21. Mechoulam R., Benshabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology. 50:1995;83-90.
22. Mechoulam R., Hanus L. A historical overview of chemical research on cannabinoids. Chemistry and Physics of Lipids. 108:2000;1-13. [Review].
23. 2+ channels in a neuronal expression system. Molecular Pharmacology. 49:1996;707-714.
24. Pertwee R.G. Neuropharmacology and therapeutic potential of cannabinoids. Addiction Biology. 5:2000;37-46.
25. Pinto J.C., Potie F., Rice K.C., Boring D., Johnson M.R., Evans D.M., Wilken G.H., Cantrell C.H., Howlett A.C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Molecular Pharmacology. 46:1994;516-522.
26. Piomelli D., Beltramo M., Giuffrida A., Stella N. Endogenous cannabinoid signaling. Neurobiology of Disease. 5:1998;462-473.
27. Porter A.C., Felder C.C. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacology and Therapeutics. 90:2001;45-60.
28. Rubino T., Patrini G., Massi P., Fuzio D., Vigano D., Giagnoni G., Parolaro D. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. Journal of Pharmacology and Experimental Therapeutics. 285:1998;813-819.
29. Savinainen J.R., Jarvinen T., Laine K., Laitinen J.T. Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent G-protein activation in rat cerebellar membranes. British Journal of Pharmacology. 134:2001;664-672.
30. Selley D.E., Rorrer W.K., Breivogel C.S., Zimmer A.M., Zimmer A., Martin B.R., Sim-Selley L.J. Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation. Journal of Neurochemistry. 77:2001;1048-1057.
31. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. Journal of Neuroscience. 16:1996;4322-4334.
32. 9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Molecular Pharmacology. 55:1999;8-13.
33. Sim L.J., Hampson R.E., Deadwyler S.A., Childers S.R. Effects of chronic treatment with delta(9)-tetrahydrocannabinol on cannabinoid-stimulated [S-35]GTP-gamma-S autoradiography in rat brain. Journal of Neuroscience. 16:1996;8057-8066.
34. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
35. 2+ transients using simultaneous microfluorimetry and electrophysiology. Pflugers Archives. 412:1988;216-223.
36. van der Stelt M., Veldhuis W.B., Bar P.R., Veldink G.A., Vliegenthart J.F., Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. Journal of Neuroscience. 21:2001;6475-6479.
37. 2+ loads. Journal of Neurophysiology. 72:1994;2563-2569.
38. Werth J.L., Thayer S.A. Mitochondria buffer physiological calcium loads in cultured rat dorsal root ganglion neurons. Journal of Neuroscience. 14:1994;348-356.
39. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 410:2001;588-592.